| Leukemia |
NCT04840784: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML |
|
|
| Terminated | 1a/1b | 9 | RoW | ETH-155008, study drug | Shengke Pharmaceuticals Pty Ltd | NHL, Leukemia | 05/23 | 05/23 | | |
NCT05003141: PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies |
|
|
| Recruiting | 1a/1b | 110 | US, RoW | PSB202 | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma | 07/23 | 01/24 | | |
| Recruiting | 1b | 156 | US | Cirmtuzumab followed by Cirmtuzumab plus ibrutinib, UC-961, Imbruvica, Cirmtuzumab plus ibrutinib, Ibrutinib | Oncternal Therapeutics, Inc, University of California, San Diego, California Institute for Regenerative Medicine (CIRM) | B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma | 04/19 | 12/22 | | |
V-FAST master, NCT04075747: A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia |
|
|
| Completed | 1b | 57 | US | CPX-351, Vyxeos, JZP351, Venetoclax, Venclexta, Midostaurin, Rydapt, Enasidenib, Idhifa | Jazz Pharmaceuticals | Acute Myeloid Leukemia | 02/22 | 09/23 | | |
| Recruiting | 1b | 136 | US | APVO436 | Aptevo Research and Development LLC | AML, MDS | 12/22 | 06/23 | | |
NCT04365179: Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML |
|
|
| Recruiting | 1b | 18 | US | Nerofe | Immune System Key Ltd, University of Miami Sylvester Comprehensive Cancer Center | Advanced MDS, AML | 12/22 | 12/22 | | |
| Completed | 1b | 241 | Europe, US, RoW | Decitabine, 5-aza-2'-deoxycytidine, PDR001, spartalizumab, MBG453, sabatolimab, Azacitidine, 5-azacytidine | Novartis Pharmaceuticals | Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Preleukemia, Bone Marrow Diseases, Hematologic Diseases, Chronic Myelomonocytic Leukemia | 09/23 | 09/23 | | |
|
|
ELEVATE, NCT04150887: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1b | 61 | Europe, Canada, US | Cusatuzumab, JNJ-74494550, ARGX-110, Azacitidine, Vidaza, Venetoclax, Venclexta | OncoVerity, Inc., argenx, Janssen Research & Development, LLC | Leukemia, Myeloid, Acute | 05/24 | 05/24 | | |
|
NCT04434196: A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Active, not recruiting | 1b | 50 | Europe, Canada, US | CC-99282, Obinutuzumab | Celgene | Lymphoma, Non-Hodgkin | 11/24 | 05/25 | | |
NCT05756777: A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) |
|
|
| Recruiting | 1b | 36 | US | Gilteritinib, Ivosidenib, Enasidenib | Memorial Sloan Kettering Cancer Center, Astellas Pharma US, Inc. | Acute Myeloid Leukemia (AML) | 02/25 | 02/25 | | |
NCT05970822: Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML |
|
|
| Recruiting | 1b | 32 | RoW | BC3402, Azacitidine | Biocity Biopharmaceutics Co., Ltd. | Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | 03/25 | 12/25 | | |
NCT05659732: A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer |
|
|
| Recruiting | 1b | 32 | RoW | PEP07 | PharmaEngine | Acute Myeloid Leukemia, Lymphoma, Mantle-Cell | 12/25 | 12/25 | | |
NCT05342584: Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS |
|
|
| Recruiting | 1b | 99 | US | Venetoclax Oral Tablet, Daunorubicin, Cytarabine | Ioannis Mantzaris, AbbVie | Acute Myeloid Leukemia, Myelodysplastic Syndromes | 12/28 | 12/28 | | |
CTR20192479: A Phase I clinical trial evaluating HD CD19 CAR-T in patients with refractory or relapsed B-cell acute lymphoblastic leukemia |
|
|
| Not yet recruiting | 1 | 18 | China | HD CD19 CAR-T - Huadao (Shanghai) Biopharmaceutical | Huadao (Shanghai) Biopharmaceutical Co., Ltd. | r/r B-ALL (refractory or relapsed B-cell acute lymphoblastic leukemia) | | | | |
CTR20191243: Safety and tolerability study of pCAR-19B in CD19-positive R/R B-ALL |
|
|
| Completed | 1 | 12 | China | pCAR-19B - Chongqing Precision Biotech | Chongqing Precision Biotechnology Co., Ltd. | CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia | | | | |
CTR20202693: Phase I clinical study of GC007g injection in the treatment of relapsed and refractory CD19-positive acute B lymphoblastic leukemia after allogeneic bone marrow transplantation |
|
|
| Completed | 1 | 18 | China | GC007G - Gracell | Genxi Biotechnology (Shanghai) Co., Ltd./Suzhou Genxi Biotechnology Co., Ltd. | Relapsed and refractory CD19-positive acute lymphoblastic leukemia | | | | |
CTR20210591: Phase I clinical study of anti-CD19 single chain antibody chimeric antigen receptor T cell injection in the treatment of B-cell acute lymphoblastic leukemia |
|
|
| Recruiting | 1 | 18 | China | CAR-T-19 injection - Immunotech Biopharm | Beijing Yongtai Ruike Biotechnology Co., Ltd. | Relapsed/refractory B-cell acute lymphoblastic leukemia | | | | |
CTR20221359: Phase I clinical study of Senl_B19 autologous T cell injection in the treatment of r/r B-ALL |
|
|
| Recruiting | 1 | 18 | China | SENL-B19 - SenlangBio | Hebei Senlang Biotechnology Co., Ltd. | Relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia | | | | |
2012-005629-65: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose-finding study |
|
|
| Ongoing | 1 | 15 | Europe | Iclusig, Film-coated tablet, Iclusig | University of Birmingham, Bloodwise TAP, Ariad Pharmaceuticals | Chronic Myeloid Leukaemia (CML) in Blast Phase, CML is a cancer of the white blood cells which build up, disrupting the normal balance of cells in the blood and bone marrow. In Blast phase, the cancer invades the bone marrow and other organs., Diseases [C] - Cancer [C04] | | | | |
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 1 | 70 | US, Europe | GDC-0199 (ABT-199), Obinutuzumab | Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd | Lymphocytic Leukemia, Chronic | 01/15 | 11/16 | | |
2009-012718-35: An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 mg adult tablet (part A) followed by an open, non-randomised multiple-doses study with adjusted doses of 6MP oral liquid formulation (part B) in children with acute lymphoblastic leukaemia. |
|
|
| | 1 | 30 | Europe | Loulla, Puri-Nethol, Loulla, Puri-Nethol, Puri-Nethol | Only For Children Pharmaceuticals | Acute Lymphoblastic Leukemia | | 02/13 | | |
NCT02312102: Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation |
|
|
| Active, not recruiting | 1 | 22 | US | Lenalidomide, Revlimid, Velcade, bortezomib | Massachusetts General Hospital, Celgene Corporation, Millennium Pharmaceuticals, Inc. | Myelodysplastic Syndrome, Acute Myeloid Leukemia | 04/17 | 08/24 | | |
NCT02091245: Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML |
|
|
| Active, not recruiting | 1 | 16 | US | KPT-330, Selinexor | Dana-Farber Cancer Institute, William Lawrence and Blanche Hughes Foundation, Karyopharm Therapeutics Inc | Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Relapsed Acute Myelogenous Leukemia (AML), Refractory Acute Myelogenous Leukemia (AML), Relapsed Mixed Lineage Leukemia, Refractory Mixed Lineage Leukemia, Relapsed Biphenotypic Leukemia, Refractory Biphenotypic Leukemia, Chronic Myelogenous Leukemia (CML) in Blast Crisis | 02/18 | 12/24 | | |
NCT02268851: A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL |
|
|
| Completed | 1 | 45 | US | TGR-1202, RP5264, Umbralisib, Ibrutinib, Imbruvica, CRA-032765, PCI-32765 | Dana-Farber Cancer Institute, TG Therapeutics, Inc., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma | 05/18 | 08/23 | | |
|
|
|
|
|
NCT01638533: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction |
|
|
| Active, not recruiting | 1 | 37 | Canada, US | Pharmacological Study, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic | National Cancer Institute (NCI), Celgene Corporation | Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm | 11/18 | 03/25 | | |
AG120-221-C-001, NCT02632708: Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation |
|
|
| Active, not recruiting | 1 | 153 | Europe, US | AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide | Institut de Recherches Internationales Servier, Celgene Corporation | Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury | 12/18 | 07/24 | | |
|
|
|
NCT06082596: Study of BEBT-908 in Subjects With Advanced Hematological Tumors |
|
|
| Completed | 1 | 32 | RoW | BEBT-908 for injection, CUDC-908 | BeBetter Med Inc | Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Multiple Myeloma | 03/19 | 03/19 | | |
2017-003935-12: A phase 1 trial to assess the safety, tolerability and anti-tumor activity of increasing doses of the drugs AZD6738 and gemcitabine in combination. |
|
|
| Not yet recruiting | 1 | 55 | Europe | Gemcitabine, AZD6738, L01BC05, Powder for solution for infusion, Film-coated tablet, Concentrate for solution for infusion, Gemcitabine | Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca | Locally advanced or metastatic solid tumour., Solid tumour cancer (any type of cancer apart from leukaemia or lymphoma) which has spread., Diseases [C] - Cancer [C04] | | | | |
NCT02280525: Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma |
|
|
| Completed | 1 | 8 | US | Lenalidomide, CC-5013, Revlimid, Rituximab, Rituxan, Fludarabine, Fludarabine Phosphate, Fludara, Cyclophosphamide, Cytoxan, Neosar, NK Cells, Cytarabine, Ara-C, Cytosar, DepoCyt, Cytosine Arabinosine Hydrochloride | M.D. Anderson Cancer Center, The Leukemia and Lymphoma Society, Celgene Corporation | Leukemia | 07/19 | 07/19 | | |
NCT02477878: Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant |
|
|
| Active, not recruiting | 1 | 10 | US | BPX-501, Rimiducid, AP1903 | Bellicum Pharmaceuticals | Leukemia, Myelodysplastic Syndromes, Lymphoma, Multiple Myeloma, Hematologic Neoplasms | 01/20 | 01/33 | | |
NCT02537613: A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 1 | 54 | US | Obinutuzumab, Gazyva, GA-101, Ibrutinib, Imbruvica | Dana-Farber Cancer Institute, Genentech, Inc. | Chronic Lymphocytic Leukemia | 03/20 | 01/29 | | |
LAM-002A/NHL, NCT02594384: A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma |
|
|
| Completed | 1 | 62 | US | LAM-002A, apilimod dimesylate, Rituximab, rituxan, Atezolizumab, Tecentriq | AI Therapeutics, Inc. | Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic | 03/20 | 03/23 | | |
| Active, not recruiting | 1 | 12 | US | acalabrutinib, ACP-196, ACP-319 | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 07/20 | 05/26 | | |
|
2018-003907-20: Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Relapsed or Refractory Lymphoblastic Lymphoma Estudio para evaluar la dosis máxima tolerada, la farmacocinética y la seguridad de ixazomib administrado por vía intravenosa a pacientes pediátricos con leucemia linfoblástica aguda en recaída o resistente o linfoma linfoblástico recidivante o refractario |
|
|
| Not yet recruiting | 1 | 18 | Europe | Ixazomib, Powder for solution for injection | Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit, Millennium Pharmaceuticals, Inc. | Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma Leucemia linfoblástica aguda en recaída o resistente y linfoma linfoblástico en recaída o resistente, Cancer Cancer, Diseases [C] - Cancer [C04] | | | | |
NCT00697684: Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant |
|
|
| Completed | 1 | 29 | US | Antithymocyte Globulin, Clofarabine | Beth Israel Deaconess Medical Center, Genzyme, a Sanofi Company | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Relapsed/Refractory Chronic Lymphocytic Leukemia, Relapsed/Refractory Non Hodgkin's Lymphoma, Hodgkins Disease, Relapsed Refractory Multiple Myeloma | 12/20 | 11/23 | | |
NCT04230473: A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia |
|
|
| Completed | 1 | 10 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Relapsed or Refractory Acute Lymphoblastic Leukemia | 12/20 | 11/22 | | |
NCT03383952: A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia |
|
|
| Recruiting | 1 | 20 | RoW | ICAR19 CAR-T cells, Biological drug | Immune Cell, Inc., Weifang People's Hospital | B Cell Leukemia, B Cell Lymphoma | 12/20 | 12/25 | | |
NCT02038777: A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies |
|
|
| Completed | 1 | 48 | Japan | PF-04449913, Low dose ARA-C (LDAC), Daunorubicin, Cytarabine, Azacitidine, LDAC | Pfizer | Acute Myeloid Leukemia | 02/21 | 12/23 | | |
NCT04176393: A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation |
|
|
| Completed | 1 | 30 | RoW | ivosidenib, TIBSOVO | CStone Pharmaceuticals | Relapsed or Refractory Acute Myeloid Leukemia | 02/21 | 01/23 | | |
|
|
NCT04439721: γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse |
|
|
| Recruiting | 1 | 5 | RoW | γδT Cell infusion agent | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Soochow University | Leukemia, B-cell | 05/21 | 05/21 | | |
| Completed | 1 | 326 | Europe, Japan, US, RoW | Asciminib (ABL001), ABL001, Nilotinib, Imatinib, Dasatinib | Novartis Pharmaceuticals | Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | 06/21 | 03/23 | | |
2018-306-00CH1, NCT04272957: A Study of HMPL-306 in Patients With IDH1 and/or IDH2 Mutation of Relapsed/Refractory Myeloid Leukemia/Neoplasms |
|
|
| Recruiting | 1 | 75 | RoW | HMPL-306 | Hutchison Medipharma Limited | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
| Active, not recruiting | 1 | 62 | Europe, US | MCLA-117 bispecific antibody, bispecific, human bispecific common light chain, bispecific IgG1 targeting CLEC12A and CD3 | Merus N.V. | Acute Myelogenous Leukemia, Acute Myeloid Leukemia | 07/21 | 07/21 | | |
|
|
|
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL |
|
|
| Active, not recruiting | 1 | 69 | US | acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan | Acerta Pharma BV | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia | 08/21 | 09/27 | | |
|
|
|
NCT02879643: Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL |
|
|
| Recruiting | 1 | 36 | Canada, US, RoW | Marqibo | Therapeutic Advances in Childhood Leukemia Consortium, Spectrum Pharmaceuticals, Inc | ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Acute | 08/21 | 12/22 | | |
NCT03042689: Study of Regorafenib in Patients With Advanced Myeloid Malignancies |
|
|
| Completed | 1 | 16 | US | Regorafenib, Stivarga | Massachusetts General Hospital, Bayer | Acute Myeloid Leukemia | 09/21 | 02/23 | | |
NCT03027102: Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1 | 24 | Canada | DNT cells | University Health Network, Toronto, Ozmosis Research Inc. | Acute Myeloid Leukemia | 09/25 | 09/25 | | |
NCT03840317: Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia |
|
|
| Active, not recruiting | 1 | 20 | RoW | Autologous CD19-targeting CAR T cells | Hebei Senlang Biotechnology Inc., Ltd., Hebei Yanda Ludaopei Hospital | Acute Lymphocytic Leukemia | 09/21 | 01/22 | | |
| Active, not recruiting | 1 | 11 | Europe | Ceralasertib, AZD6738, Acalabrutinib, ACP196 | Acerta Pharma BV | Chronic Lymphocytic Leukemia | 09/21 | 06/24 | | |
|
|
NCT05404282: A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) |
|
|
| Active, not recruiting | 1 | 11 | Europe | Ceralasertib, AZD6738, Acalabrutinib, ACP196 | AstraZeneca | Chronic Lymphocytic Leukemia | 09/21 | 06/23 | | |
NCT04204161: A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma |
|
|
| Recruiting | 1 | 30 | RoW | CAR-T19/CAR-T22 | Shenzhen BinDeBio Ltd., Xiangya Hospital of Central South University | Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood, Refractory B-cell Acute Lymphoblastic Leukemia, Childhood, Relapsed/Refractory B-cell Lymphoma, Childhood | 10/21 | 10/24 | | |
NCT03524235: Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL |
|
|
| Active, not recruiting | 1 | 30 | US | Total Body Irradiation, TBI, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion, Bendamustine, Bendeka; Treanda, Fludarabine, Fludara, Rituximab, Rituxan | Noah Merin, Miltenyi Biomedicine GmbH, Teva Branded Pharmaceutical Products R&D, Inc. | Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma | 11/21 | 11/31 | | |
NCT03515512: IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation |
|
|
| Completed | 1 | 23 | US | Enasidenib, idhifa | Massachusetts General Hospital, Celgene | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | 12/21 | 02/23 | | |
|
NCT03798509: Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | Human CD19 targeted T Cells Injection | Hrain Biotechnology Co., Ltd., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | CD19-positive, Acute Lymphoblastic Leukemia | 01/22 | 01/24 | | |
NCT04888442: Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL |
|
|
| Recruiting | 1 | 18 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | 01/22 | 03/22 | | |
NCT03271515: Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL |
|
|
| Not yet recruiting | 1 | 20 | RoW | anti-CD19 anti-CD20 Bispecific CAR-T | Beijing Doing Biomedical Co., Ltd. | Leukemia, Lymphoma | 03/22 | 03/23 | | |
NCT02546739: Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL |
|
|
| Not yet recruiting | 1 | 100 | RoW | Anti-CD19-CAR | Beijing Doing Biomedical Co., Ltd., The First Hospital of Jilin University, Hebei Yanda Ludaopei Hospital | Leukemia, Lymphoma | 03/22 | 03/23 | | |
NCT03910842: Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy |
|
|
| Recruiting | 1 | 12 | RoW | CD19-TriCAR-T/SILK | Timmune Biotech Inc., Hunan Provincial People's Hospital | Non-Hodgkin Lymphoma of Intestine, Leukemia | 04/22 | 10/22 | | |
NCT02303392: Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma |
|
|
| Active, not recruiting | 1 | 34 | US | Selinexor, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Pharmacological Study, pharmacological studies, Laboratory Biomarker Analysis | Jennifer Woyach, Karyopharm Therapeutics Inc | Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | 04/22 | 12/22 | | |
NCT03770429: AZD6738 for Patients With Progressive MDS or CMML |
|
|
| Recruiting | 1 | 52 | US | AZD6738 | Massachusetts General Hospital, AstraZeneca | Leukemia, Myelodysplastic Syndrome | 05/24 | 05/25 | | |
NCT04264078: Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | CD7 UCAR-T cells, Fludarabine, Cytoxan, Melphalan | Xinqiao Hospital of Chongqing, Gracell Biotechnology Shanghai Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, Central South University, The First Affiliated Hospital of Kunming Medical College, The General Hospital of Western Theater Command, Second Affiliated Hospital of Xi'an Jiaotong University, Nanfang Hospital of Southern Medical University, Fujian Medical University Union Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital | T-cell Leukemia, T-cell Lymphoma | 06/22 | 06/23 | | |
NCT04008251: Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies |
|
|
| Recruiting | 1 | 10 | RoW | Second generation humanized CAR-T cells | Wuhan Sian Medical Technology Co., Ltd, Wuhan Union Hospital, China, Jingzhou Central Hospital, Xiangyang Central Hospital, People Hospital Of Yichang | Acute Lymphoblastic Leukemia, B Cell Lymphoma | 07/22 | 12/22 | | |
NCT04480788: CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study |
|
|
| Recruiting | 1 | 9 | RoW | T cell injection targeting CD7 chimeric antigen receptor | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University | T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-negative, T-cell Lymphoblastic Leukemia | 08/22 | 08/22 | | |
8479217, NCT06469138: A Phase 1 Study to Investigate 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects |
|
|
| Completed | 1 | 6 | Europe | Bemcentinib, BGB324 | BerGenBio ASA | Non-Small Cell Lung Cancer, Metastatic Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Metastatic Pancreatic Cancer, Glioblastoma, Malignant Mesothelioma, COVID-19 | 09/22 | 09/22 | | |
| Terminated | 1 | 11 | US | CPX-351, Vyxeos, Gemtuzumab Ozogamicin, Mylotarg | Weill Medical College of Cornell University, Jazz Pharmaceuticals, Pfizer | Acute Myeloid Leukemia | 08/22 | 09/22 | | |
| Completed | 1 | 4 | Canada, US | Carfilzomib, Cyclophosphamide, Etoposide | Stanford University, Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen | Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia, Refractory Leukemia | 08/21 | 11/23 | | |
CTR20190521: Clinical study on the safety of QHRD107 capsules |
|
|
| Completed | 1 | 24 | China | QHRD107 - Qianhong Bio-Pharma | Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. | Acute myeloid leukemia (AML) | | | | |
NCT02334865: SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy |
|
|
| Active, not recruiting | 1 | 18 | US | Incomplete Freund's Adjuvant, Freund's Incomplete Adjuvant, IFA, ISA-51, Montanide ISA 51, Montanide ISA-51, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, SVN53-67/M57-KLH Peptide Vaccine | Roswell Park Cancer Institute, Celgene | Partial Response of Multiple Myeloma or Plasma Cell Leukemia, Plasma Cell Myeloma | 09/22 | 05/26 | | |
NCT03795779: CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies |
|
|
| Recruiting | 1 | 20 | RoW | CLL1-CD33 cCAR T cells | iCell Gene Therapeutics, The General Hospital of Western Theater Command, iCAR Bio Therapeutics Ltd., Peking University Shenzhen Hospital | Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Chronic Myeloid Leukemia | 09/22 | 09/22 | | |
NCT03991884: Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia |
|
|
| Completed | 1 | 24 | US | Etoposide, 33419-42-0, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, 141540, Doxorubicin, 14-Hydroxydaunomycin, 23214-92-8, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Vincristine, 22-Oxovincaleukoblastine, LEUROCRISTINE, VCR, Vincrystine, Prednisone, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Metacortandracin, Ofisolona, Orasone, Paracort, Predicor, Predicorten, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Cyclophosphamide, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclostin, Cyclostine, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Inotuzumab Ozogamicin, 635715-01-4, Besponsa, CMC-544, Way 207294, WAY-207294 | University of Washington, Pfizer | Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma | 10/22 | 06/23 | | |
NCT04896112: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia |
|
|
| Withdrawn | 1 | 93 | US | LNK01002, LNK-1000318 | Lynk Pharmaceuticals Co., Ltd | Acute Myeloid Leukemia, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera | 10/22 | 10/22 | | |
NCT03412292: MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) |
|
|
| Recruiting | 1 | 30 | RoW | MAX-40279, MAX-40279-001 | Maxinovel Pty., Ltd. | Acute Myelogenous Leukemia (AML) | 11/22 | 12/22 | | |
NCT05144347: Study of XL114 in Subjects With Non-Hodgkin's Lymphoma |
|
|
| Terminated | 1 | 2 | US | XL114 | Exelixis | Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 11/22 | 11/22 | | |
2021-002333-42: Safety and Efficacy of OC-1 Cell Therapy in Patients With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma Seguridad y eficacia de la terapia de células OC-1 en pacientes con leucemia o linfoma linfoblástico agudo de células T en recaída o refractario |
|
|
| Not yet recruiting | 1 | 24 | Europe | OC-1, Solution for infusion | OneChain Immunotherapeutics, OneChain Immunotherapeutics | Children older than 2 years or adults, male and female, with refractory or relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma (T-ALL/LL). Niños mayores de 2 años o adultos, hombres y mujeres, con leucemia linfoblástica aguda de células T/linfoma linfoblástico (T-ALL/LL) refractario o recidivante., Lymphoblastic leukaemia / Lymphoblastic lymphoma Leucemia linfoblástica aguda / Linfoma linfoblástico, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
NCT05215015: Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | Anti-CD33/CLL1 CAR-NK Cells | Wuxi People's Hospital, Imbioray (Hangzhou) Biomedicine Co., Ltd. | Acute Myeloid Leukemia | 11/22 | 11/22 | | |
NCT04187495: Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) |
|
|
| Recruiting | 1 | 30 | RoW | MAX-40279-01 | Maxinovel Pty., Ltd. | AML | 12/22 | 12/22 | | |
NCT04599556: Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy |
|
|
| Recruiting | 1 | 81 | RoW | anti-CD7 CAR-T | Zhejiang University, Yake Biotechnology Ltd. | CD7+ Acute Leukemia, CD7+ Lymphoma | 12/23 | 12/25 | | |
NCT05077423: A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Terminated | 1 | 3 | US | CD33*CD3 BsAb, CD33xCD3 | Y-mAbs Therapeutics, Children's Oncology Group | AML, Childhood | 12/22 | 12/22 | | |
NCT05454098: Clifutinib Food Effect Study in Healthy Subjects |
|
|
| Completed | 1 | 40 | RoW | Clifutinib with fed state, Clifutinib with fasted state | Sunshine Lake Pharma Co., Ltd. | Acute Myeloid Leukemia in Children | 12/22 | 12/22 | | |
2022-000380-46: A Phase I/Ib Study of JNJ-75276617 in Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias Estudio fase I/Ib de JNJ-75276617 en sujetos pediátricos y adultos jóvenes con leucemias agudas en recaída o refractarias |
|
|
| Ongoing | 1 | 80 | Europe | JNJ-75276617, Powder for oral solution | Janssen-Cilag International NV, Janssen Research & Development, LLC | Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations Leucemias agudas en recaída/refractarias que albergan alteraciones genéticas de KMT2A, NPM1 o nucleoporina, Relapsed/Refractory Acute Leukemias Leucemias agudas en recaída/refractarias, Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 1 | 35 | US, RoW | APG2575 | Ascentage Pharma Group Inc. | CLL/SLL | 03/25 | 06/26 | | |
NCT02512497: Romidepsin Maintenance After Allogeneic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 10 | US | Romidepsin, Istodax, Depsipeptide, FK228, Busulfan, Busulfex, Myleran, Fludarabine, Fludarabine Phosphate, Fludara, Stem Cell Transplant, Thymoglobulin, ATG, Rabbit Antithymocyte Globulin, Rabbit Antilymphocyte Globulin, Rabbit ATG, rATG | Ohio State University Comprehensive Cancer Center, Celgene Corporation | Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma | 12/22 | 12/22 | | |
NCT04827069: A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML) |
|
|
| Recruiting | 1 | 80 | RoW | Clifutinib Besylate, HEC73543 | Sunshine Lake Pharma Co., Ltd. | Acute Myeloid Leukemia | 12/22 | 03/23 | | |
NCT04839341: Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients |
|
|
| Recruiting | 1 | 12 | RoW | Uproleselan, GMI-1271 | Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd | Relapsed/Refractory AML | 12/22 | 02/23 | | |
NCT03739554: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL |
|
|
| Completed | 1 | 5 | US | CYC065, Venetoclax, ABT-199 | Cyclacel Pharmaceuticals, Inc. | Relapsed or Refractory Chronic Lymphocytic Leukemia | 11/22 | 04/23 | | |
NCT05127135: Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | ThisCART7 cells | Fundamenta Therapeutics, Ltd., The First Affiliated Hospital of University of Science and Technology of China | T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma | 01/23 | 12/23 | | |
| Recruiting | 1 | 62 | US | Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto | Ascentage Pharma Group Inc. | Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia | 01/24 | 01/24 | | |
NCT05259813: Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL |
|
|
| Withdrawn | 1 | 12 | RoW | JWCAR029 (Relmacabtagene Autoleucel) | Shanghai Ming Ju Biotechnology Co., Ltd., The First Affiliated Hospital with Nanjing Medical University | Leukemia, Lymphocytic, Chronic, B-Cell | 01/23 | 03/25 | | |
NCT05740917: To Evaluate the Phase I Clinical Study of XZB-0004 in Patients With AML and MDS |
|
|
| Not yet recruiting | 1 | 82 | RoW | XZB-0004 | Xuanzhu Biopharmaceutical Co., Ltd. | AML, MDS | 02/23 | 02/23 | | |
NCT04637009: A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms |
|
|
| Terminated | 1 | 20 | Canada, US | TAS1553 | Astex Pharmaceuticals, Inc. | Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm | 02/23 | 02/23 | | |
NCT03541369: Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Terminated | 1 | 64 | Europe, Canada, Japan, US, RoW | AMG 427, AMG 427; 20170528 | Amgen | Relapsed/Refractory Acute Myeloid Leukemia (AML) | 02/23 | 02/23 | | |
NCT04443751: A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1 | 31 | RoW | SHR-1702 | Jiangsu HengRui Medicine Co., Ltd. | AML, MDS | 02/23 | 02/23 | | |
AMELI-01, NCT03190278: Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 65 | US | UCART123v1.2 | Cellectis S.A. | Relapsed/Refractory Acute Myeloid Leukemia | 12/24 | 12/24 | | |
|
|
|
NCT03513484: Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1 | 44 | US | Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef | Northwestern University, Robert H. Lurie Cancer Center, Boehringer Ingelheim, National Cancer Institute (NCI) | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | 12/25 | 01/27 | | |
NCT04243785: A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome |
|
|
| Recruiting | 1 | 80 | US | BTX-A51, Azacitidine | Edgewood Oncology Inc. | Acute Myeloid Leukemia, Myelodysplastic Syndrome | 03/26 | 03/27 | | |
NCT04604691: Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) |
|
|
| Recruiting | 1 | 20 | RoW | Blinatumomab for Injection | Seoul National University Hospital, Amgen | Pediatric ALL, B Cell, Minimal Residual Disease | 03/23 | 12/24 | | |
NCT04796675: Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies |
|
|
| Recruiting | 1 | 27 | RoW | Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells | Wuhan Union Hospital, China, Shanghai Simnova Biotechnology Co.,Ltd. | Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin's Lymphoma | 03/23 | 03/24 | | |
NCT03103971: huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia |
|
|
| Terminated | 1 | 55 | US | Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes huJCAR014, Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes huJCAR014, Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes, huJCAR014, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Laboratory Biomarker Analysis, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Pharmacological Study | Fred Hutchinson Cancer Center, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Adult Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory B Acute Lymphoblastic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | 03/23 | 03/24 | | |
NCT03751709: Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL |
|
|
| Active, not recruiting | 1 | 10 | US | Blinatumomab, Blincyto, Haplo-Mismatched Cell Therapy (HMCT), HMCT; 'primary DLI; 'microtransplantation' | Cedars-Sinai Medical Center, Amgen | B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL | 03/23 | 03/25 | | |
NCT04679194: Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT |
|
|
| Terminated | 1 | 11 | US | Mana 312 | Mana Therapeutics | AML/MDS | 03/23 | 03/23 | | |
